Ascentage Pharma Group (AAPG): Earnings growth forecast for next year
Ascentage Pharma Group (AAPG) is facing a liquidity shortage and the depletion of reserves due to development costs. However, Ascentage Pharma Group (AAPG) is rapidly gaining traction in global oncology as a bold innovator. The projected growth in earnings per share for the next fiscal year visualizes these expectations, where the 7.30 mark records this indicator. In the future, drug approvals will ensure ultra-high margins driven by patent monopolies.
Metric breakdowns and analytics for Ascentage Pharma Group International (AAPG)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt and liquidity details:
Total Debt to Capital Ascentage Pharma Group|AAPG - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ascentage Pharma Group|AAPG - Company Aggregate Debt|Debt to Book Value Ascentage Pharma|AAPG - Amount of Long-Term Liabilities|Company Short-Term Debts Ascentage Pharma|Quick Ratio ascentage.com
- net income and valuation ratios data:
AAPG - Annual Net Income|Projected Future Earnings Ascentage Pharma Group|AAPG - Market Cap to Earnings|Projected Price to Earnings Ascentage Pharma|AAPG - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ascentage Pharma Group|AAPG - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Ascentage Pharma|AAPG - Earnings per share for the trailing year|Quarterly EPS earnings growth ascentage.com|AAPG - Earnings growth in current year|Net earnings per share growth forecast for next year Ascentage Pharma Group
- revenue and sales details:
General company analysis:Ascentage
To minimize risks, it is essential for investors to track the consensus net income per share forecast, which reflects the expected return on equity for the year ahead. When assessing the projected EPS growth for next year, one should consider the full capacity utilization of Ascentage Pharma Group (AAPG) biotechnological laboratories, which confirms the operational stability and fundamental reliability of the business as it scales drug production.
Direct competitors
ONC (BeiGene Ltd) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Therapeutics HALO|Net earnings per share growth forecast for next year Revolution Medicines, Inc. (RVMD)|Expected earnings per share growth for next year CG Oncology CGON|Net earnings per share growth forecast for next year UroGen URGN|Consensus forecast of earnings per share growth for next year Bicara Bio (BCAX)|PSNL - Net earnings per share growth forecast for next year|ERAS - Earnings growth forecast for next year|DCTH: Earnings growth forecast for next year|Y-mAbs Therapeutics, Inc. (YMAB) - Earnings growth forecast for next year|Expected earnings per share growth for next year AURA|Expected net earnings per share growth next year candeltx.com CADL|Earnings growth forecast for next year ARAY|SLS (SELLAS Life Sciences Group, Inc.) - Expected earnings per share trend next year|Earnings growth forecast for next year ACTU (Actuate Therapeutics Inc)|Expected earnings per share trend next year CTOR|tuhurabio.com - Earnings growth forecast for next year|Expected earnings per share trend next year TARA (Protara Therapeutics)|Fate Therapeutics, Inc. (FATE) - Net earnings per share growth forecast for next year|WHWK - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year tscan.com|CSBR: Expected earnings per share trend next year|Net earnings per share growth forecast for next year XBiotech USA (XBIT)|CVM: Net earnings per share change forecast for next year|Net earnings per share growth forecast for next year ostherapies.com OSTX|Projected earnings per share increase next year RADX (Radiopharm Theranostics Limited)|Artiva - Earnings growth forecast for next year|ANL: Net earnings per share growth forecast for next year|VERU: Earnings growth forecast for next year|Net earnings per share change forecast for next year TPST (Tempest Tx)|XLO (Xilio Therapeutics) - Earnings growth forecast for next year|Expected net earnings per share growth next year renovarobio.com RENB|Net earnings per share growth forecast for next year muraloncology.com (MURA)|Projected earnings per share increase next year KAPA|Earnings growth forecast for next year OKUR (onkuretherapeutics.com)|Projected earnings per share increase next year GDTC (CytoMed)|Curis - Earnings growth forecast for next year|APLM: Net earnings per share growth forecast for next year|Tharimmune (THAR) - Net earnings per share growth forecast for next year|Expected earnings per share growth for next year Advanced Biomed Inc.|GNPX (Genprex Inc) - Earnings growth forecast for next year|Calidi Biotherapeutics (CLDI) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year SBFM|Net earnings per share growth forecast for next year XBIO (Xenetic Biosciences, Inc.)|Earnings growth forecast for next year SLRX (salariuspharma.com)|PPBT - Expected earnings per share growth for next year|AONC - Net earnings per share growth forecast for next year|Expected earnings per share trend next year BGNE (BeOne Medicines)|CKPT: Earnings growth forecast for next year|Elevation Oncology Inc. (ELEV) - Earnings growth forecast for next year|ICAD (iCAD) - Earnings growth forecast for next year|Earnings growth forecast for next year ikenaoncology.com|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year Viracta Therapeutics Inc. (VIRX)|Net earnings per share growth forecast for next year MorphoSys Inc MOR|Expected earnings per share trend next year NAYA|AAPGV: Expected earnings per share growth for next year
